# FGF2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - FGF2 (bFGF) is a pleiotropic growth factor encoded by a gene on chromosome 4q28.1, acting as a ligand for FGFR1-4 and influencing cell proliferation, differentiation, migration, and survival. - The FGF2 gene exhibits complex regulation, including alternative translation initiation from non-AUG codons producing distinct low (LMW, 18 kDa) and high (HMW, 22-34 kDa) molecular weight isoforms with differential subcellular localization and functions. - Dysregulation of FGF2 signaling is implicated in numerous pathologies, notably oncogenesis (promoting angiogenesis, proliferation, and metastasis) and fibrotic diseases (e.g., renal, pulmonary, hepatic fibrosis), with specific SNPs in its promoter and 3' UTR linked to disease risk and progression. - FGF2 mediates its effects primarily through canonical receptor tyrosine kinase (RTK) signaling via RAS-MAPK and PI3K-AKT pathways, but also exhibits non-canonical and intracrine functions, including nuclear translocation of HMW isoforms to regulate gene expression. - Therapeutic strategies target the FGF/FGFR axis, with FDA-approved FGFR inhibitors (e.g., erdafitinib, pemigatinib) used in cancer treatment, and ongoing research exploring FGF2's role in neurodegenerative disorders, metabolic conditions, and tissue regeneration. --- ## Executive Summary & Key Metadata Fibroblast growth factor 2 (FGF2), also known as basic fibroblast growth factor (bFGF), is a multifunctional polypeptide that belongs to the FGF family of signaling molecules. The gene encodes a protein that is a potent mitogen, angiogenic factor, and neurotrophic factor, exerting pleiotropic effects on cell proliferation, differentiation, migration, and survival across a broad spectrum of tissues and developmental stages. The FGF2 protein is a canonical ligand for the fibroblast growth factor receptors (FGFR1-4), with the highest affinity for the IIIc splice variant of FGFR1 and FGFR2. The gene is subject to complex transcriptional and post-transcriptional regulation, including alternative translation initiation from non-AUG codons, alternative splicing, and extensive post-translational modifications. Dysregulation of FGF2 expression or signaling is implicated in a wide array of pathologies, including oncogenesis, fibrosis, neurodegeneration, and metabolic disorders. | Attribute | Value | | :--- | :--- | | **HGNC Symbol** | FGF2 | | **UniProt Accession** | P09038 | | **Representative PDB ID** | 1FGA (and others; see Section 2) | | **Chromosomal Locus** | 4q28.1 (GRCh38/hg38) | | **Primary Molecular Function** | Growth factor activity; heparin binding; FGFR receptor tyrosine kinase activation | | **Disease & Pathology Associations** | Cancer (multiple types), fibrosis (renal, pulmonary, hepatic), atherosclerosis, osteoarthritis, neurodegenerative disorders, diabetic wound healing, myopia | | **Key Isoforms** | Low molecular weight (LMW, 18 kDa) and high molecular weight (HMW, 22-34 kDa) isoforms | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human FGF2 gene is located on the long arm of chromosome 4 at cytogenetic band q28.1, a locus established through radiation hybrid mapping. The gene spans approximately 38 kilobases (kb) of genomic DNA on the plus strand. The genomic architecture is complex, featuring multiple promoters, a large 5' untranslated region (UTR), and three coding exons (exons 1, 2, and 3) that are subject to complex alternative splicing and alternative translation initiation. The core open reading frame (ORF) for the canonical 18 kDa isoform is distributed across exons 1-3, with the start codon located in exon 1. The promoter region of FGF2 is TATA-less and GC-rich, characteristic of housekeeping and growth factor genes. It contains multiple Sp1 transcription factor binding sites, which are critical for basal transcriptional activity. The 5' flanking region also harbors several regulatory elements, including a functional polymorphism at position -553 (T/A) that has been associated with altered transcriptional activity and increased breast cancer risk in Polish women. This polymorphism is located within a putative regulatory region and may affect the binding affinity of transcription factors, thereby modulating FGF2 expression levels. ### 1.2 Promoter Architecture and Transcriptional Regulation The FGF2 gene is regulated by a complex interplay of transcription factors, enhancers, and epigenetic modifiers. The core promoter region contains binding sites for a variety of transcription factors, including: - **Sp1**: Essential for basal promoter activity. - **AP-1 (Activator Protein-1)**: Mediates responses to phorbol esters, growth factors, and cytokines. - **Egr-1 (Early Growth Response 1)**: A key mediator of FGF2 induction in response to cellular stress, such as autophagy and ischemia-reperfusion injury. - **HoxA10**: A homeodomain transcription factor that directly activates FGF2 transcription in myeloid progenitor cells, contributing to myeloid leukemogenesis. - **GATA4**: Mediates angiotensin II (Ang II)-induced FGF2 gene activation in cardiomyocytes through the ERK1/2 and p38 MAPK pathways. - **YAP (Yes-associated protein)**: A transcriptional co-activator that promotes FGF2 transcription in response to radiation, contributing to glioma radioresistance. - **STAT3**: A downstream effector of FGF2 signaling that can further induce FGF2 expression, creating a positive feedback loop in renal fibrosis. The FGF2 promoter also contains a functional cAMP-response element (CRE) and a binding site for the transcription factor COUP-TFII, which is itself induced by FGF2 via the MEK1/2 pathway, forming a negative feedback loop that inhibits osteoblast differentiation. ### 1.3 Alternative Splicing and Isoform Diversity The FGF2 gene produces multiple mRNA transcripts through alternative splicing and the use of alternative polyadenylation signals. The most well-characterized isoforms arise from alternative translation initiation, not alternative splicing. The gene contains three in-frame CUG codons upstream of the canonical AUG start codon, all located within an extended 5' region of the mRNA. Translation initiation from these non-AUG codons produces the high molecular weight (HMW) isoforms of FGF2 (22, 22.5, 24, and 34 kDa), while initiation from the canonical AUG codon produces the low molecular weight (LMW) 18 kDa isoform. The HMW isoforms contain an N-terminal extension rich in arginine and glycine residues, which functions as a nuclear localization signal (NLS). Consequently, HMW FGF2 isoforms are predominantly localized to the nucleus, where they exert intracrine functions, such as regulating gene expression and cell cycle progression. In contrast, the LMW 18 kDa isoform is primarily cytoplasmic and is the major secreted form, acting in a paracrine and autocrine manner. The differential expression of these isoforms has significant functional consequences. For example, ablation of the LMW isoform accelerates murine osteoarthritis, while loss of HMW isoforms offers protection, indicating opposing roles in joint homeostasis. Similarly, knockout of LMW FGF2 attenuates atherosclerosis by reducing macrophage infiltration and oxidative stress. Alternative polyadenylation (APA) also contributes to FGF2 transcript diversity. The 3' UTR of FGF2 is unusually long and contains multiple polyadenylation signals. The use of these alternative signals generates transcripts with 3' UTRs of varying lengths, which can influence mRNA stability, localization, and translational efficiency. The alternative polyadenylation writer CSTF2 has been shown to form a positive feedback loop with FGF2, promoting tubular epithelial-mesenchymal transition and renal fibrosis. ### 1.4 Post-Transcriptional Regulation by Non-Coding RNAs The long 3' UTR of FGF2 is a major target for microRNA (miRNA) regulation. Numerous miRNAs have been identified that directly bind to the FGF2 3' UTR and repress its expression, including: - **miR-195**: Targets FGF2 to inhibit epithelial-mesenchymal transition (EMT) in prostate cancer cells and reverses cisplatin resistance in non-small cell lung cancer (NSCLC). - **miR-203**: Inhibits renal cancer cell proliferation, migration, and invasion by targeting FGF2. - **miR-202**: Inhibits cell migration and invasion through targeting FGF2 and inactivating Wnt/β-catenin signaling in endometrial carcinoma. - **miR-155**: Inversely correlates with esophageal cancer progression through regulating tumor-associated macrophage FGF2 expression. - **miR-9-5p**: Derived from BMSC exosomes, alleviates spinal cord injury by regulating the HDAC5/FGF2 axis. - **miR-221-3p**: Derived from BMSC exosomes, alleviates asthma progression by targeting FGF2 and inhibiting the ERK1/2 signaling pathway. - **miR-21-3p**: Suppresses autophagy of bovine ovarian granulosa cells through the AKT/mTOR pathway by targeting FGF2. - **miR-424-5p**: Mediates the effect of lncRNA SNHG1 on osteosarcoma cell proliferation, migration, and invasion. - **miR-338-3p**: Mediates the effect of circ_0000615 on nasopharyngeal cancer development. - **miR-299-3p**: Mediates the effect of lncRNA RHPN1-AS1 on cervical cancer progression. - **miR-16**: Sponged by lncRNA WWC2-AS1 to regulate FGF2 expression in radiation-induced intestinal fibrosis. - **miR-196a-3p**: A functional SNP in the FGF2 3' UTR regulated by this miRNA is associated with bone mineral density in the Chinese population. - **miR-194**: Inhibits innate antiviral immunity by targeting FGF2 in influenza H1N1 virus infection. - **miR-23c**: Inhibits articular cartilage damage recovery by regulating MSC differentiation to chondrocytes via reducing FGF2. Long non-coding RNAs (lncRNAs) also regulate FGF2 expression by acting as competing endogenous RNAs (ceRNAs) or miRNA sponges. Examples include SNHG1 in osteosarcoma, RHPN1-AS1 in cervical cancer, and WWC2-AS1 in radiation-induced intestinal fibrosis. Furthermore, N6-methyladenosine (m6A) RNA modification plays a role in FGF2 regulation. The m6A reader protein YTHDF3 modulates the progression of breast cancer cells by regulating FGF2 through m6A methylation. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The canonical human FGF2 protein (UniProt P09038) is a 288-amino acid polypeptide for the HMW isoforms, while the LMW 18 kDa isoform is 155 amino acids in length. The protein adopts a canonical β-trefoil fold, a structure shared by all FGF family members. This fold consists of 12 antiparallel β-strands arranged into three-fold internal symmetry, forming a barrel-like structure with a central hydrophobic core. The domain architecture can be delineated as follows: - **N-terminal region (residues 1-133 for HMW isoforms)**: This region is unique to the HMW isoforms and contains the nuclear localization signal (NLS). It is intrinsically disordered and rich in arginine and glycine residues. This domain is responsible for the nuclear targeting of HMW FGF2 and its intracrine functions. - **Core FGF homology domain (residues 134-288 for HMW; 1-155 for LMW)**: This region encompasses the entire LMW isoform and contains the receptor-binding and heparin-binding sites. It is composed of the 12 β-strands (β1-β12) that form the β-trefoil structure. - **Heparin-binding site**: A cluster of basic residues (lysine and arginine) located on the surface of the β-trefoil domain, primarily within the loops connecting β-strands. This site mediates binding to heparan sulfate proteoglycans (HSPGs), which is essential for high-affinity binding to FGFRs and for the formation of stable FGF2-FGFR-HSPG signaling complexes. - **FGFR-binding site**: A discontinuous epitope composed of residues from multiple β-strands and loops. This site interacts with the immunoglobulin-like domains D2 and D3 of FGFR1-4. The primary binding interface involves the "β4-β5 loop" and the "β8-β9 loop" of FGF2. ### 2.2 Secondary and Tertiary Structure The β-trefoil fold of FGF2 is a highly stable structure, with a melting temperature above 60°C. The 12 β-strands are arranged in three repeating units of four strands each (β1-β4, β5-β8, β9-β12). Each unit forms a β-hairpin and a β-arch, contributing to the overall globular shape. The loops connecting the β-strands are of variable length and are often involved in ligand binding and protein-protein interactions. The structure is stabilized by a network of hydrogen bonds and hydrophobic interactions within the core. The protein contains no disulfide bonds, which contributes to its relatively high conformational flexibility compared to other growth factors. ### 2.3 Quaternary Structure and Ligand Binding FGF2 exists as a monomer in solution. However, upon binding to its receptors, it forms a ternary complex with FGFR and heparin. The stoichiometry of the signaling complex is 2:2:2 (two FGF2, two FGFR, and two heparin molecules). The binding of FGF2 to the FGFR ectodomain induces receptor dimerization, which is further stabilized by heparin bridging. This dimerization brings the intracellular tyrosine kinase domains of the FGFRs into close proximity, facilitating trans-autophosphorylation and activation of downstream signaling cascades. The interaction between FGF2 and heparin is critical for its biological activity. Heparin binding protects FGF2 from thermal denaturation and proteolytic degradation, and it is required for the high-affinity binding of FGF2 to FGFRs. The heparin-binding site is a shallow groove on the surface of the β-trefoil domain, lined with basic residues that interact with the negatively charged sulfate groups of heparin. ### 2.4 Structural Insights from PDB Entries Multiple high-resolution crystal structures of FGF2 have been determined, both alone and in complex with its receptors and heparin. Representative PDB entries include: - **1FGA**: The first crystal structure of human FGF2, solved at 1.6 Å resolution. This structure revealed the canonical β-trefoil fold. - **1CVS**: Structure of FGF2 in complex with a heparin-derived disaccharide, revealing the heparin-binding site. - **1EV2**: Structure of the FGF2-FGFR1 complex, providing the first detailed view of the ligand-receptor interface. - **3OJM**: Structure of the FGF2-FGFR1-heparin ternary complex, illustrating the complete signaling assembly. These structures have been instrumental in understanding the molecular basis of FGF2 signaling and in the rational design of FGF2 inhibitors. > **Interactive 3D Protein Visualizer: Load FGF2 (PDB: 1FGA)** > > Explore the three-dimensional structure of the FGF2 protein in detail. This interactive tool allows you to rotate, zoom, and inspect the β-trefoil fold, the heparin-binding site, and the FGFR-binding interface. > > [**Launch the Interactive 3D Protein Visualizer**](/tools/protein-structure-viewer?source=alphafold&accession=P09038) ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical FGFR Signaling FGF2 exerts its primary biological effects by binding to and activating fibroblast growth factor receptors (FGFR1-4), which are receptor tyrosine kinases (RTKs). The binding of FGF2 to the extracellular domain of FGFRs, in conjunction with heparan sulfate proteoglycans (HSPGs), induces receptor dimerization and trans-autophosphorylation of specific tyrosine residues in the intracellular kinase domain. These phosphorylated tyrosines serve as docking sites for downstream signaling molecules, activating several key signaling cascades: - **RAS-MAPK Pathway**: This is the most extensively studied pathway downstream of FGF2. The adaptor protein FRS2 (fibroblast growth factor receptor substrate 2) is constitutively associated with the FGFR juxtamembrane region. Upon receptor activation, FRS2 is phosphorylated, creating binding sites for the adaptor protein GRB2, which recruits the guanine nucleotide exchange factor SOS to the plasma membrane. SOS activates RAS, which in turn activates the RAF-MEK-ERK kinase cascade. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as ELK1, c-FOS, and c-JUN, regulating genes involved in cell proliferation, differentiation, and survival. This pathway is critical for FGF2-induced cell proliferation and is a major target for cancer therapy. - **PI3K-AKT Pathway**: FGF2 also activates phosphatidylinositol 3-kinase (PI3K) through the recruitment of the regulatory subunit p85 to phosphorylated FRS2 or to the docking protein GAB1. PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which recruits AKT to the plasma membrane, where it is phosphorylated and activated by PDK1 and mTORC2. Activated AKT promotes cell survival, growth, and metabolism by phosphorylating a wide range of substrates, including BAD, FOXO, and GSK3β. This pathway is particularly important for FGF2-mediated cell survival and is implicated in the enhanced proliferation and adipogenic differentiation of adipose stem cells. - **PLCγ-Ca²⁺ Pathway**: FGF2 binding also leads to the phosphorylation and activation of phospholipase Cγ (PLCγ), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 triggers the release of calcium from intracellular stores, while DAG activates protein kinase C (PKC). This pathway is involved in the regulation of cell migration and cytoskeletal reorganization. - **STAT Pathway**: FGF2 can also activate signal transducers and activators of transcription (STATs), particularly STAT3, either directly through FGFR-associated kinases or indirectly through other pathways. STAT3 activation by FGF2 has been implicated in the pathogenesis of renal tubulointerstitial fibrosis. ### 3.2 Non-Canonical and Intracrine Signaling In addition to its canonical paracrine/autocrine signaling through cell-surface FGFRs, FGF2 also has important intracrine functions. The HMW isoforms of FGF2, which contain an NLS, are translocated to the nucleus where they can directly regulate gene expression. Nuclear FGF2 has been shown to interact with chromatin and modulate the activity of transcription factors, such as CREB-binding protein (CBP)/p300. This intracrine signaling is independent of FGFR activation and is involved in the regulation of cell proliferation and survival. FGF2 can also signal through integrins. The LMW isoform has been shown to bind to integrin αvβ3, which can activate downstream signaling pathways such as FAK and SRC, contributing to cell adhesion and migration. This integrin-mediated signaling is particularly relevant in the context of cancer cell invasion and metastasis. ### 3.3 Regulation of Gene Expression FGF2 regulates the expression of a vast array of genes, depending on the cell type and context. It is a master regulator of angiogenesis, inducing the expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors. In fibroblasts, FGF2 modulates the expression of genes involved in extracellular matrix (ECM) remodeling, including matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). RNA sequencing analysis of FGF2-responsive transcriptomes in skin fibroblasts has identified a broad network of genes involved in cell cycle, migration, and ECM organization. FGF2 also plays a critical role in the regulation of cell fate decisions. For example, it is a well-known inhibitor of myogenic differentiation, repressing the expression of MyoD. In osteoblasts, FGF2 inhibits differentiation by inducing COUP-TFII expression via the MEK1/2 pathway. In neural progenitor cells, FGF2 promotes proliferation and inhibits differentiation, maintaining the stem cell pool. ### 3.4 Protein-Protein Interaction Networks The FGF2 signaling network is highly interconnected. Key protein-protein interactions include: - **FGF2-FGFR1**: The primary receptor interaction, which is essential for most of FGF2's biological functions. This interaction is enhanced by heparin. - **FGF2-HSPG**: Heparan sulfate proteoglycans act as co-receptors, concentrating FGF2 at the cell surface and presenting it to FGFRs. - **FGF2-Integrin αvβ3**: A direct interaction that mediates non-canonical signaling and cell adhesion. - **FRS2-FGFR**: The key adaptor protein that links FGFR activation to the RAS-MAPK and PI3K-AKT pathways. - **YAP-FGF2**: YAP is a downstream effector of the FGF2/STAT3 pathway, and it also promotes FGF2 transcription, creating a positive feedback loop. - **S100A4-FGF2**: S100A4 is involved in the stimulatory effects elicited by the FGF2/FGFR1 signaling pathway in triple-negative breast cancer cells. ### 3.5 Role in Development and Tissue Homeostasis FGF2 is a critical regulator of embryonic development. It is expressed in the neuroepithelium during embryonic brain development, where it promotes the proliferation of neural progenitors. In the developing limb, FGF2 is involved in the formation of the apical ectodermal ridge (AER) and the maintenance of the underlying mesenchyme. FGF2 also plays a role in the development of the skeletal system, cardiovascular system, and various organs. In adult tissues, FGF2 is involved in tissue repair and regeneration. It is a potent angiogenic factor, promoting the formation of new blood vessels during wound healing and in response to ischemia. FGF2 also promotes the proliferation of various stem and progenitor cells, including mesenchymal stem cells (MSCs), which are important for tissue regeneration. FGF2 gene transfer has been shown to restore hippocampal functions in mouse models of Alzheimer's disease, highlighting its role in neuroprotection and cognitive function. ```mermaid sequenceDiagram participant HSPG as "Heparan Sulfate Proteoglycan" participant FGF2 as "FGF2 Ligand" participant FGFR as "FGFR (Receptor Tyrosine Kinase)" participant FRS2 as "FRS2 Adaptor" participant GRB2 as "GRB2/SOS Complex" participant RAS as "RAS GTPase" participant MAPK as "RAF/MEK/ERK Cascade" participant PI3K as "PI3K/AKT Pathway" participant PLC as "PLCγ Pathway" participant NUC as "Nucleus" HSPG->>FGF2: Presents ligand FGF2->>FGFR: Binds to D2/D3 domains FGFR->>FGFR: Dimerization & trans-autophosphorylation FGFR->>FRS2: Phosphorylates FRS2 FRS2->>GRB2: Recruits GRB2/SOS GRB2->>RAS: Activates RAS RAS->>MAPK: Activates RAF/MEK/ERK MAPK->>NUC: Phosphorylates transcription factors (ELK1, c-FOS) FGFR->>PI3K: Activates PI3K (via GAB1) PI3K->>NUC: Activates AKT (pro-survival signaling) FGFR->>PLC: Activates PLCγ PLC->>NUC: Generates DAG & IP3 (Ca2+ release, PKC activation) NUC->>NUC: Regulates gene expression (proliferation, differentiation, survival) ``` ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Single Nucleotide Polymorphisms (SNPs) and Disease Association The FGF2 gene is highly polymorphic, and numerous SNPs have been identified in its promoter, coding, and non-coding regions. These SNPs have been associated with a wide range of diseases and traits. #### 4.1.1 Promoter Polymorphisms - **-553 T/A (rs3083959)**: This SNP is located in the promoter region of FGF2. The A allele has been associated with increased breast cancer risk in Polish women. The mechanism is thought to involve altered transcription factor binding, leading to increased FGF2 expression and enhanced angiogenesis and tumor growth. - **-834 C/T**: A polymorphism in the promoter region that has been studied for its association with various conditions, though results have been inconsistent. #### 4.1.2 3' UTR Polymorphisms - **rs1048201 (C/T)**: This SNP is located in the 3' UTR of FGF2 and is regulated by miR-196a-3p. The T allele creates a binding site for miR-196a-3p, leading to reduced FGF2 expression. This SNP is associated with bone mineral density (BMD) in the Chinese population, with the T allele conferring a protective effect against osteoporosis. - **rs3083954 (C/G)**: Another 3' UTR SNP that has been studied for its association with various diseases, including diabetic peripheral neuropathy (DPN). A study in Han Chinese patients found a correlation between SNPs at the 3' UTR of FGF2 and their interaction with environmental factors in DPN patients. #### 4.1.3 Coding Region Polymorphisms While missense mutations in the FGF2 coding region are relatively rare, some have been identified. However, the functional consequences of most of these variants are not well characterized. Given the critical role of FGF2 in development, complete loss-of-function mutations are likely to be embryonic lethal. ### 4.2 FGF2 in Cancer FGF2 is a well-established oncogene and a key driver of tumor angiogenesis. Overexpression of FGF2 is observed in a wide variety of solid tumors, including breast, lung, prostate, gastric, colorectal, and ovarian cancers. FGF2 promotes tumor growth and metastasis through multiple mechanisms: - **Angiogenesis**: FGF2 is a potent inducer of new blood vessel formation, which is essential for tumor growth beyond a few millimeters in size. - **Proliferation**: FGF2 directly stimulates the proliferation of tumor cells through the RAS-MAPK and PI3K-AKT pathways. - **Invasion and Metastasis**: FGF2 promotes epithelial-mesenchymal transition (EMT), a process by which epithelial cells acquire mesenchymal properties, enabling them to invade surrounding tissues and metastasize to distant sites. - **Stemness**: Chronic exposure to FGF2 can convert induced pluripotent stem cells (iPSCs) into cancer stem cells with an enhanced integrin/focal adhesion/PI3K/AKT axis. - **Chemoresistance**: FGF2 signaling has been implicated in resistance to chemotherapy. For example, miR-195-5p reverses cisplatin resistance in NSCLC by targeting FGF2. FGF2-FGFR1 pathway activation is also induced in pemetrexed-resistant lung cancer cells. Specific examples of FGF2's role in cancer include: - **Gastric Cancer**: FGF2 drives tumor-associated macrophage infiltration via the serine protease PRSS23. Dihydroartemisinin inhibits vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway. - **Breast Cancer**: FGF2 is implicated in breast cancer development and progression. The -553 T/A polymorphism is associated with increased risk. YTHDF3 modulates breast cancer progression by regulating FGF2 through m6A methylation. S100A4 is involved in the stimulatory effects of the FGF2/FGFR1 pathway in triple-negative breast cancer (TNBC). - **Colorectal Cancer**: FGF2 gene expression is evaluated as a potential biomarker and therapeutic target. - **Osteosarcoma**: The lncRNA SNHG1/miR-424-5p/FGF2 axis promotes osteosarcoma cell proliferation, migration, and invasion. - **Nasopharyngeal Cancer**: The circ_0000615/miR-338-3p/FGF2 axis is involved in nasopharyngeal cancer development. - **Cervical Cancer**: The lncRNA RHPN1-AS1/miR-299-3p/FGF2 axis promotes cervical cancer cell proliferation, invasion, and migration. - **Endometrial Carcinoma**: miR-202 inhibits cell migration and invasion by targeting FGF2 and inactivating Wnt/β-catenin signaling. - **Prostate Cancer**: miR-195 inhibits EMT by targeting FGF2. - **Renal Cell Carcinoma**: miR-203 inhibits renal cancer cell proliferation, migration, and invasion by targeting FGF2. - **Esophageal Cancer**: miR-155 inversely correlates with disease progression through regulating tumor-associated macrophage FGF2 expression. - **Glioma**: Radiation-induced YAP activation promotes FGF2 transcription, conferring radioresistance. - **Ovarian Cancer**: Polymorphisms in the FGF2 gene have been studied for their association with serous ovarian cancer risk. ### 4.3 FGF2 in Fibrotic Diseases FGF2 has a dual role in fibrosis, acting as both a pro-fibrotic and anti-fibrotic factor depending on the tissue and context. - **Renal Fibrosis**: FGF2 is a key driver of renal fibrosis. Autophagy activates EGR1 via the MAPK/ERK pathway to induce FGF2 in renal tubular cells, leading to fibroblast activation and fibrosis during maladaptive kidney repair. YAP1 is a downstream effector of the FGF2/STAT3 pathway in the pathogenesis of renal tubulointerstitial fibrosis. The alternative polyadenylation writer CSTF2 forms a positive feedback loop with FGF2 to promote tubular EMT and renal fibrosis. - **Pulmonary Fibrosis**: FGF2 is implicated in the pathogenesis of pulmonary fibrosis, where it promotes fibroblast proliferation and ECM deposition. - **Hepatic Fibrosis**: FGF2 regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling, contributing to liver fibrosis. - **Intestinal Fibrosis**: The lncRNA WWC2-AS1/miR-16/FGF2 axis is involved in radiation-induced intestinal fibrosis. - **Cardiac Fibrosis**: FGF2 is involved in the fibrotic response following myocardial infarction. Conversely, in the skin, FGF2 acts as an anti-fibrotic agent. FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts. FGF2 also has antifibrotic activity in wound healing. ### 4.4 FGF2 in Metabolic and Skeletal Disorders - **Obesity**: FGF2 influences adipocyte differentiation. Polymorphisms in the FGF2 gene are associated with obesity phenotypes in the Han Chinese population. FGF2 disruption enhances thermogenesis in brown and beige fat, protecting against adiposity and hepatic steatosis. FGF2 also plays a role in the adipogenic impairment of adipose tissue-derived mesenchymal stem cells in subjects with metabolic syndrome. - **Osteoporosis**: FGF2 is a susceptibility gene for osteoporosis. A functional SNP in the 3' UTR of FGF2 is associated with bone mineral density. FGF2 positively regulates osteoclastogenesis via the ERK-CREB pathway. - **Osteoarthritis**: Ablation of the LMW FGF2 isoform accelerates murine osteoarthritis, while loss of HMW isoforms offers protection. - **Atherosclerosis**: FGF2 is involved in carotid atherosclerotic plaque development. Knockout of LMW FGF2 attenuates atherosclerosis by reducing macrophage infiltration and oxidative stress. - **Myopia**: FGF2 has been implicated in the development of myopia. ### 4.5 FGF2 in Neurological and Psychiatric Disorders - **Alzheimer's Disease**: FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease. - **Depression**: Saikosaponin d downregulates microRNA-155 and upregulates FGF2 to improve depression-like behaviors in rats. FGF2 gene polymorphisms also affect SSRI treatment response and side effects. - **Spinal Cord Injury**: Exosomal miR-9-5p derived from BMSCs alleviates apoptosis, inflammation, and ER stress in spinal cord injury by regulating the HDAC5/FGF2 axis. FGF2-pretreated human dental pulp cells have been used in a rat spinal cord injury model. - **Schwann Cells**: FGF2 negatively regulates the P0 gene in Schwann cells, which is relevant to peripheral nerve myelination. ### 4.6 FGF2 in Reproductive Biology FGF2 plays a critical role in reproduction. It is expressed in the uterine endometrium during estrous and is important for the continuation of pregnancy in ruminants. FGF2 gene expression is also studied in pre-implantation developmental stages of in vitro-produced sheep embryos. In bovine granulosa cells, the cAMP-EPAC pathway mediates PGE2-induced FGF2 expression. FGF2 also affects cumulus cell expansion, in vitro embryo production, and gene expression in buffalo. ### 4.7 FGF2 in Wound Healing and Tissue Regeneration FGF2 is a critical factor in wound healing and tissue regeneration. It promotes the proliferation of fibroblasts, keratinocytes, and endothelial cells, and stimulates angiogenesis. FGF2 gene-activated matrices promote the proliferation of bone marrow stromal cells. Idebenone-loaded wound dressings promote diabetic wound healing through the upregulation of the FGF2 gene. Collagen-heparin-FGF2-VEGF scaffolds induce a regenerative gene expression profile in a fetal sheep wound model. Gene electrotransfer of FGF2 enhances collagen scaffold biocompatibility for tendon repair. ## 5. Host-Pathogen & Viral Interactions FGF2 is involved in the host response to various pathogens, and several viruses have evolved mechanisms to exploit FGF2 signaling for their own benefit. ### 5.1 Viral Interactions - **Influenza A Virus (IAV)**: FGF2 plays a role in IAV-induced lung injury. miR-194 inhibits innate antiviral immunity by targeting FGF2 in influenza H1N1 virus infection. This suggests that FGF2 has a protective role in the host defense against IAV. - **Coxsackievirus B3 (CVB3)**: CVB3 has been engineered as a gene therapy vector to express functional FGF2. This demonstrates the potential of using viruses as delivery vehicles for FGF2-based therapies. - **Human Immunodeficiency Virus (HIV)**: While not directly studied in the provided literature, FGF2 has been shown to modulate HIV replication in other studies. FGF2 can enhance HIV replication in macrophages and may contribute to HIV-associated neurocognitive disorders. ### 5.2 Bacterial Interactions - **Lipopolysaccharide (LPS)**: LPS is a component of the outer membrane of Gram-negative bacteria. Mesenchymal stem cell-based FGF2 gene therapy has been shown to protect against acute lung injury induced by LPS in mice. This suggests that FGF2 has anti-inflammatory properties that can mitigate the effects of bacterial endotoxins. ### 5.3 Parasitic Interactions - While not directly studied in the provided literature, FGF2 has been implicated in the pathogenesis of malaria and other parasitic infections, where it may contribute to angiogenesis and tissue remodeling. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors FGF2 and its receptors are attractive therapeutic targets for a variety of diseases, particularly cancer and fibrotic disorders. ### 6.1 FDA-Approved Drugs Targeting the FGF/FGFR Axis While there are no FDA-approved drugs that directly target FGF2, several drugs target the FGFRs, which are the primary receptors for FGF2. These include: - **Erdafitinib (Balversa)**: An FGFR1-4 inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations. - **Pemigatinib (Pemazyre)**: An FGFR1-3 inhibitor approved for the treatment of previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. - **Infigratinib (Truseltiq)**: An FGFR1-3 inhibitor approved for the treatment of previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. - **Futibatinib (Lytgobi)**: An irreversible FGFR1-4 inhibitor approved for the treatment of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene rearrangements or fusions. These inhibitors block the kinase activity of FGFRs, thereby preventing the activation of downstream signaling pathways by FGF2 and other FGF ligands. ### 6.2 Investigational Drugs and Small-Molecule Inhibitors - **Dihydroartemisinin (DHA)**: A derivative of artemisinin, a natural product used to treat malaria. DHA has been shown to inhibit vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway. - **Meclozine**: An antihistamine that has been developed as an inhibitor of FGFR3 to treat achondroplasia. Meclozine attenuates the MAPK ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)